SCINAI IMMUNOTHERAPEUTICS LT earnings calls

SCNI · every analyst question and management's answer

Aug 26, 2026 earnings call — CDMO expansion and commercial execution

Scinai expanded CDMO operations after the Recipharm acquisition and reported approximately $3.1 million of committed customer orders as of August 16.

Revenue $0.0B · EPS $-0.74

Key quotes

"That transaction added much more than equipment and infrastructure, it added an experienced operating team, established quality systems, technical know-how, customer relationships, and additional manufacturing capabilities."
— Amir Reichman (CEO) · CDMO expansion

"The most significant accounting item was the approximately $6.4 million bargain purchase gain associated with the Recipharm transaction."
— Amir Reichman (CEO) · Financial and accounting effects

"On the R&D side, our focus is increasingly on prioritization and capital discipline."
— Amir Reichman (CEO) · R&D prioritization

AI-generated notes on the earnings call transcript. Quotes are taken from the transcript. This is not a FolioObs investment view.

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) · Earnings calendar

Other earnings calls this week

GOOGL · ALPHABET INC — Gemini 4 models and Cloud TPU scaling
AMZN · AMAZON.COM INC — AWS AI growth and company results
MSFT · MICROSOFT CORP — Copilot expansion and AI-driven Azure growth
GOOG · ALPHABET INC-CL C — Gemini 4 launch and Cloud TPU scaling
V · VISA INC — Tokenization, VAS growth, and agentic commerce focus
MA · MASTERCARD INCORPORATED — Network expansion and agentic commerce push
SPGI · S&P GLOBAL INC — Strategic review of Capital IQ and data businesses
DASH · DOORDASH INC - A — Instacart deal and DashMart expansion

All of this week's earnings call summaries